340B Drug Pricing Program
The AHA, joined by several other national groups representing 340B hospitals, today urged the Health Resources and Services Administration to extend the timeline for stakeholder comments, agency consideration, and manufacturer rebate plan submissions for its 340B Rebate Model Pilot Program.
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the timeline for stakeholder comments, agency consideration and manufacturer rebate plan submissions for its 340B Rebate Model Pilot Program.
AHA, health associations initial comment on the Health Resources and Services Administration’s (HRSA) notice of a 340B Rebate Model Pilot Program.
AHA Defends HHS Court Decision on 340B Rebate Model
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to prevent drug companies from implementing a 340B rebate model. The brief was filed in a consolidated appeal involving five drug companies. The AHA…
ORAL ARGUMENT NOT YET SCHEDULEDNos. 25-5177, 25-5179, 25-5220, 25-5221, 25-5236___________________________________________________United States Court of Appealsfor the District of Columbia Circuit_______________________________________________
The Health Resources and Services Administration (HRSA) July 31 announced a 340B rebate model pilot program that will provide certain drugmakers the option to effectuate access to 340B discounted pricing for certain drugs under a rebate model.
The Health Resources and Services Administration (HRSA) July 31 announced a 340B rebate model pilot program that will provide certain drugmakers the option to effectuate access to 340B discounted pricing for certain drugs under a rebate model.
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug manufacturers to effectuate the 340B ceiling price on select drugs to all 340B-covered entities.
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug manufacturers to effectuate the 340B ceiling price on select drugs to all 340B covered entities.